Cholinesterase inhibitors: relating pharmacological properties to clinical profiles: Introduction
Farlow, M.R.
International journal of clinical practice. Supplement 2002(127): 1-5
2002
ISSN/ISBN: 1368-504X PMID: 12139364 Document Number: 549354
Document emailed within 1 workday
Related Documents
Domino, E.F. 1987: Comparative seizure inducing properties of various cholinesterase inhibitors: antagonism by diazepam and midazolam Neurotoxicology 8(1): 113-122Rangoonwala, B.; Rosenthal, I. 1998: Management of hypertension and its sequelae with ACE inhibitors: biochemical, pharmacological and clinical aspects International Journal of Clinical Practice 52(7): 492-500
Mashkovskiĭ, M.D.; Iuzhakov, S.D.; Absava, G.I.; Erokhina, L.G.; Lebedeva, N.V. 1984: Pharmacological properties and clinical use of xanthinol nicotinate Klinicheskaia Meditsina 62(11): 30-34
Jerie, P.; Kremer, H.J. 1992: Renpress, Sandopril (Spirapril/TI 211-950). Summary of chemical, pharmacological and clinical properties Cor et Vasa 34(1): 82-87
Pineo, G.F.; Hull, R.D. 2004: Dalteparin: pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic diseases European Journal of Medical Research 9(4): 215-224
Petroianu, G.A.; Moshnin, W. 2008: The history of cholinesterase inhibitors: who was Moschnin(e)? Die Pharmazie 63(4): 325-327
Ellis, J.M. 2005: Cholinesterase inhibitors in the treatment of dementia Journal of the American Osteopathic Association 105(3): 145-158
Hitzeman, N. 2006: Cholinesterase inhibitors for Alzheimer's disease American Family Physician 74(5): 747-749
Borchert, K.; Pietsch, P.; Busch, H. 1972: Use of cholinesterase inhibitors in postoperative care Zentralblatt für Chirurgie 97(4): 111-116
Celdrán, E.; Bekett, P.R.; Roberts, D.J. 1976: An experimental and clinical pharmacological study of the influence of triamterene on the diuretic and saluretic properties of furosemide xantinol Arzneimittel-Forschung 26(11): 2073-2076
Ikonomoff, S.I. 1973: Effect of cholinesterase inhibitors in hysteric stupor Münchener Medizinische Wochenschrift 115(16): 701-703
Vasenina, E.E. 2013: Cholinesterase inhibitors in the treatment of mixed dementia Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 113(7 Part 2): 98-103
Tonkopiĭ, V.D. 1975: Mechanism of the hypothermic action of reversible cholinesterase inhibitors Farmakologiia i Toksikologiia 38(2): 141-144
Sinforiani, E.; Banchieri, L.M.; Zucchella, C.; Bernasconi, L.; Nappi, G. 2003: Cholinesterase inhibitors in Alzheimer's disease: efficacy in a non-selected population Functional Neurology 18(4): 233-237
Natoff, I.L. 1970: Influence of the route of exposure on the acute toxicity of cholinesterase inhibitors Arhiv Za Higijenu Rada i Toksikologiju 21(4): 347-352
Williamson, A.M.; Sarvey, J.M. 1985: Effects of cholinesterase inhibitors on evoked responses in field CA1 of the rat hippocampus Journal of Pharmacology and Experimental Therapeutics 235(2): 448-455
Richard, E.; van Gool, W.A. 2006: Cholinesterase inhibitors in dementia: the precarious balance between efficacy and safety Nederlands Tijdschrift Voor Geneeskunde 150(10): 530-532
Gindilis, A.L.; Kurochkin, I.N. 1998: Potentiometric electrodes for determining choline, butyrylcholine and cholinesterase inhibitors Prikladnaia Biokhimiia i Mikrobiologiia 34(3): 326-331
Zhang, S.S.; Ji, Q.E. 1987: Synthesis of 5-(1,3,3-trisubstituted) indolinyl-N,N-dimethylcarbamates as reversible cholinesterase inhibitors Yao Xue Xue Bao 22(2): 107-113
Balashova, E.K.; Pevzner, D.L.; Rozengart, V.I.; Sherstobitov, O.E. 1974: Determination of hydrophobic organic phosphorus cholinesterase inhibitors in the blood Laboratornoe Delo 12: 719-720